GILD · News · 20260820N
Revenue Performance and Mix
GILEAD SCIENCES, INC. · 2026-08-20 · Importance 47 · Surprise 22 · No source text
Gilead Sciences reported quarterly revenue of approximately $7.8 billion for the second quarter of 2026. Revenue increased 10.6% year over year, exceeding the materiality threshold and indicating strong annual growth. Third-party reporting attributed investor support to strong performance in Gilead’s HIV portfolio, although no segment-level dollar breakdown or sequential comparison was provided.
Key facts
- Gilead Sciences Q2 2026 revenue increased 10.6% year-over-year. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +10.6% | Gilead Sciences Q2 2026 revenue increased 10.6% year-over-year. |